Six women have been diagnosed with breast cancer after a review of assessments made in Oxfordshire.
Thirty women were recalled following concerns over screenings for the disease made by the same radiologist. They were identified by Oxford University Hospitals NHS Trust after a review of the 626 women seen between 2011 and 2014.
A formal investigation has been carried out by Public Health England, the NHS Breast Screening Programme and the Trust. A statement confirmed that a radiologist had not undertaken assessments since the outset of investigation.
A firm of solicitors is holding an open day on 8 January for women who may be concerned and seeking legal support.
Video report. A ten-year-old golden Labrador has been trained to become a medical detection dog - after sniffing our breast cancer in her owner.
It is Breast Cancer Awareness Month and a woman from Brighton is documenting her battle with the disease, as well as raising awareness and thousands for charity, by shaving her hair and wearing different 'head gear' each day.
Andy Dickenson reports. You can sponsor Sara Cutting here.
A woman from Brighton who was diagnosed with breast cancer in July has had her head shaved for charity. Sara Cutting is hoping to raise awareness of the condition and its impact. She is wearing a different sort of 'headgear' every day.
Former breast cancer patients and those recently diagnosed with the disease - have begun a campaign to build a new specialist unit in Wiltshire.
Three quarters of a million pounds is needed for the dedicated centre at Salisbury District Hospital which would be able to treat four and a half thousand women each year. Penny Silvester reports.
There's condemnation from Cancer Charities that a drug which can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.
Kadcyla has shown remarkable success in trials at The Queen Alexandra Hospital in Portsmouth, and a woman from Reading says it's extended her life by three years.
But it costs 90 thousand pounds for a course of treatment, too much for the NHS financial watchdog, NICE, which made the decision. It has criticised the manufacturers for the high cost.
Rachel Hepworth speaks to cancer survivors Manjinder Coulter and Kimberly Mawby, Chief Exec of NICE, Andrew Dillon, Sarah Rawlings from the charity Breakthrough Cancer, and Jennifer Cozzone from pharmaceutical company Roche.
A drug that can extend the lives of some women with an advanced form of breast cancer has been rejected for NHS use because it is too expensive.
The high price of Kadcyla makes it "impossible" to recommend for widespread use in the health service, the National Institute for Health and Care Excellence (Nice) said.
The drug, also known as trastuzumab emtansine, is used to treat breast cancer patients with HER2-positive breast cancer that has spread to other parts of the body. It is used when the cancer cannot be surgically removed and the patient has stopped responding to initial treatments.
It can offer these women a last hope, extending the lives of patients by around six months.
But final draft guidance from Nice says that the drug, which costs around £90,000 per patient at its full price, it too expensive to recommend for widespread use in the health service.
A patient using the breast cancer drug Kadcyla, which could be blocked from routine NHS access because it is too expensive, told ITV News the treatment had improved her quality of life.
"I was in quite a bad state, and within about two cycles my life felt like it had turned a corner. I was able to do things I wasn't able to do prior to being on this treatment," Mani said of the drug, which currently costs around £90,000 per patient.
A drug that was trialled in Portsmouth and can prolong the lives of breast cancer sufferers by nearly six months has been refused by the NHS because of costs.The Herceptin type drug was trialled in Portsmouth but can cost up to £90,000 per patient.
We speak to National Institute for Health and Care Excellence's Andrew Dillion about the new drug and what he thinks about the NHS' decision to refuse the expensive treatment.
The watchdog, which decides which new medicines are cost effective, said its guidance for Kadcyla, manufactured by Roche, or trastuzumab emtansine, was in draft form and is now up for public consultation.
Meanwhile patients will be able to apply to their local NHS and to the Cancer Drugs Fund.